Altamira Therapeutics Ltd CYTO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray
-
Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results
-
Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024
-
Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering
-
Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering
-
Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia
-
Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11
-
Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark
Trading Information
- Previous Close Price
- $0.63
- Day Range
- $0.61–0.66
- 52-Week Range
- $0.60–17.20
- Bid/Ask
- $0.60 / $0.63
- Market Cap
- $2.38 Mil
- Volume/Avg
- 27,856 / 443,159
Key Statistics
- Price/Earnings (Normalized)
- 0.06
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy and viral infections, and inner ear disorders. Its product Bentrio is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows to deliver of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 12
Valuation
|
Metric
|
CYTO
|
|---|---|
Price/Earnings (Normalized) | 0.06 |
Price/Book Value | 0.27 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CYTO
Financial Strength
|
Metric
|
CYTO
|
|---|---|
Quick Ratio | 0.15 |
Current Ratio | 0.43 |
Interest Coverage | — |
Quick Ratio
CYTO
Profitability
|
Metric
|
CYTO
|
|---|---|
Return on Assets (Normalized) | −28.58% |
Return on Equity (Normalized) | −114.44% |
Return on Invested Capital (Normalized) | −63.15% |
Return on Assets
CYTO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pvhjnzmg | Szr | $518.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Nfpcnqpf | Jmqtqr | $119.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ffszgmtj | Nzlxtj | $114.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Zhhkhtqv | Mmwznk | $34.9 Bil | |||
| argenx SE ADR
ARGX
| Zrnrkymcq | Nmsq | $32.9 Bil | |||
| BioNTech SE ADR
BNTX
| Yjvzwtkwn | Swmfn | $28.3 Bil | |||
| Moderna Inc
MRNA
| Tfpztsb | Vddh | $24.3 Bil | |||
| United Therapeutics Corp
UTHR
| Pjyfqfsbt | Snl | $15.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Pfwxsdns | Ghjgqm | $13.3 Bil | |||
| Incyte Corp
INCY
| Hxqmqtqm | Ykxwp | $13.0 Bil |
United States